Search Results

You are looking at 201 - 210 of 2,716 items for :

  • Refine by Access: All x
Clear All
Full access

Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2− Breast Cancer

reviews current endocrine treatment strategies and recent and ongoing studies of combination therapies in metastatic HR+, HER2-negative (HER2−) breast cancer. ET The estrogen receptor (ER) plays a fundamental role in the development and progression

Full access

Optimal Treatment of Unresectable Nonmelanoma Skin Cancers

Thomas Olencki

significance from studies with small numbers of patients. During his presentation at the NCCN 19th Annual Conference, Dr. Olencki reviewed some of the less-than-optimal treatments of the past and some of the more promising contemporary therapies for patients

Full access

Monitoring Molecular Response to Tyrosine Kinase Therapy in Chronic Myelogenous Leukemia

Jerald P. Radich

imatinib or who have resistant disease, the newest-generation agents bosutinib or ponantinib may offer promise. Dr. Radich briefly reviewed the clinical trial data behind the use of nilotinib and dasatinib in CML, 3 - 6 suggesting that they appear to be

Full access

Revisiting Minimally Invasive Surgery in the Management of Early-Stage Cervical Cancer

Kathryn P. Pennington, Renata R. Urban, and Heidi J. Gray

review, and lack of data on patient race and ethnicity. Nonetheless, reported overall inclusion characteristics, postoperative histopathologic findings, and rates of adjuvant treatment were similar between groups. Findings from a recent population

Full access

Hematopoietic Progenitor Cell Transplantation in Children, Adolescents, and Young Adults With Relapsed Mature B-Cell NHL

Aliza Gardenswartz and Mitchell S. Cairo

therapy, with varying outcomes as delineated in Table 2 . This review outlines autologous, allogeneic, tandem HCT; maintenance therapy after stem cell transplantation; and the role of CAR T-cell therapy as it relates to HCT as therapies for R/R B

Full access

Modification and Implementation of NCCN Guidelines™ on Lymphomas in the Middle East and North Africa Region

Ali Bazarbachi, Hamdy A. Azim, Hussain Alizadeh, Mahmoud Aljurf, Ibrahim Barista, Naeem A. Chaudhri, Zahira Fahed, Omar A. Fahmy, Ardeshir Ghavamzadeh, Mohamed H. Khalaf, Sami Khatib, Aghiad Kutoubi, Semra Paydas, Hanadi Rafii Elayoubi, Ghazi Zaatari, Hamdy M. Zawam, and Andrew D. Zelenetz

disparities in the availability of resources at diagnostic and treatment levels. A critical need exists for regional guidelines on cancer care, including those for lymphoid malignancies. A panel of lymphoma experts from MENA reviewed the 2009 version of the

Full access

Update on Safety of ESAs in Cancer-Induced Anemia

John Glaspy

of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 70% minimum passing score and complete the evaluation at www

Full access

Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma

Timothy M. Schmidt and Natalie S. Callander

-up. Kyle found that most patients would never develop a symptomatic disorder. This review addresses MGUS and the related entity smoldering multiple myeloma (SMM). The International Myeloma Working Group (IMWG) defines MGUS as the presence of a monoclonal

Full access

Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Philippe Armand, Celeste M. Bello, Cecil M. Benitez, Philip J. Bierman, Kirsten M. Boughan, Bouthaina Dabaja, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Alex F. Herrera, Ephraim P. Hochberg, Jiayi Huang, Patrick B. Johnston, Mark S. Kaminski, Vaishalee P. Kenkre, Nadia Khan, Ryan C. Lynch, Kami Maddocks, Jonathan McConathy, Matthew McKinney, Monika Metzger, David Morgan, Carolyn Mulroney, Rachel Rabinovitch, Karen C. Rosenspire, Stuart Seropian, Randa Tao, Jane N. Winter, Joachim Yahalom, Jennifer L. Burns, and Ndiya Ogba

80 patients (66.3%; 95% CI, 54.8–76.4) as determined by an independent radiologic review committee and at a median follow-up of 8.9 months. 159 Extended follow-up of the CheckMate 205 trial analyzed the safety and efficacy of nivolumab in patients

Full access

Multidisciplinary Management of Locally Advanced Rectal Cancer: Neoadjuvant Approaches

Swaminathan Murugappan, William P. Harris, Christopher G. Willett, and Edward Lin

cancer, requiring specific multimodality approaches. This article reviews the biology, risk factors, and evolving treatment of LARC. Important advances have been made in the past 3 decades in the multimodality treatment of patients with LARC. In the